A drug that is effective against some women’s cancers also has antitumor activity in certain cases of prostate cancer, potentially opening the way to new, targeted treatments of the most common cancer among males,
according to the lead article in the Oct. 29 issue of The New England Journal of Medicine. It reported findings from a clinical trial, a study supported in part by the Stand Up To Cancer (SU2C)- Prostate Cancer Foundation Dream Team grant, which may allow doctors to predict ahead of time which patients will benefit from the treatment. The New England Journal of Medicine is considered the most widely read, cited, and influential general medical periodical in the world.
Published on the same day was a report on chimeric antigen receptor (CAR) T-cell therapy. The treatment, which is still in development, has saved the lives of children with severe leukemia but is foiled in some cases by the development of resistance.
The SU2C-St. Baldrick’s Foundation Dream Team on pediatric cancer identified causes of the resistance in a paper published in Cancer Discovery, a leading journal of cancer research that is published by the American Association for Cancer Research.